Bruce E. Johnson, MD, FASCO

ASCO PRESIDENT Bruce E. Johnson, MD, FASCO, commented on these study findings during the press briefing. 

“This study adds to a growing body of knowledge showing the value of integrating patient-reported outcomes into routine oncology practice for symptom monitoring that a wide variety of our patients can participate in. We think this will increasingly become a way of getting timely information for both recognizing and treating symptoms, which will ultimately lead to reduced complications. This is particularly important in head and neck cancer, where people commonly have a lot of side effects….” ■

DISCLOSURE: Dr. Johnson has received research funding from Novartis and Toshiba and has patents and other intellectual property with royalties from Dana-Farber Cancer Institute.